ClinicalTrials.gg
TerminatedNCT00523042iINHALE 9Updated Sep 5, 2018

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma

A Phase 3 interventional study of insulin aspart and inhaled human insulin in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-05.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus.

Enrollment
38th of 41
10 · median 60
Started
2007
with 8 others
Phase 3
18 of 41
none open now
Registered
14th of 41
by date
Lead sponsor
19 of 41
Novo Nordisk A/S

Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, this one is the 38th largest by enrollment, is one of 9 that started in 2007, is one of 18 in phase 3, and was the 14th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Europe, Asia, Oceania and the United States of America (USA).

This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.

Read the detailed description

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or type 2 diabetes
  • Treatment with insulin and/or oral anti-diabetic drugs
  • Asthma for at least 6 months
  • Positive airway reversibility/bronchoprovocation test or documented positive test in the last 3 years
  • less than or equal to 11.0 %
  • (BMI) less than or equal to 40.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Current smoking or smoking within the last 6 months
  • Other current acute or chronic pulmonary disease excluding asthma
  • Recurrent severe hypoglycaemia
  • Proliferative retinopathy or maculopathy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    A

    Drug: inhaled human insulin

  • Active comparator
    B

    Drug: insulin aspart

Interventions

  • Treat-to-target dose titration scheme, injection s.c.

    Also known as: NovoRapid®, NovoLog®

  • Treat-to-target dose titration scheme, inhalation.

06

What researchers measure

Primary outcomes

  1. Changes in lung function, chest X-rays, or asthma exacerbation frequency

    Time frame: after 52 weeks of treatment

Secondary outcomes

  1. Diabetes control measured by change in HbA1c

    Time frame: from baseline to end of treatment

  2. Laboratory assessments (biochemistry, insulin antibodies, blood count)

    Time frame: from baseline to end of treatment

  3. Preprandial insulin doses

    Time frame: for the duration of the trial

07

Study locations

32 sites
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70112, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64108, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43210, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030, United States
  • Novo Nordisk Investigational Site
    Ogden, Utah 84403, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99208, United States
  • Novo Nordisk Investigational Site
    Broadmeadow, New South Wales 2292, Australia
  • Novo Nordisk Investigational Site
    Camperdown, New South Wales 2050, Australia
  • Novo Nordisk Investigational Site
    Keswick, South Australia 5035, Australia
  • Novo Nordisk Investigational Site
    Box Hill, Victoria 3128, Australia
  • Novo Nordisk Investigational Site
    East Ringwood, Victoria 3135, Australia
  • Novo Nordisk Investigational Site
    Parkville, Victoria 3052, Australia
  • Novo Nordisk Investigational Site
    Auchenflower, 4066, Australia
  • Novo Nordisk Investigational Site
    Kippa Ring, 4021, Australia
  • Novo Nordisk Investigational Site
    Belgrade, 11000, Former Serbia and Montenegro
  • Novo Nordisk Investigational Site
    Chandigarh, Punjab 160012, India
  • Novo Nordisk Investigational Site
    Vellore, Tamil Nadu 632004, India
  • Novo Nordisk Investigational Site
    Kolkata, West Bengal 700020, India
  • Novo Nordisk Investigational Site
    Hyderabad, 600034, India
  • Novo Nordisk Investigational Site
    Mumbai, 400 067, India
  • Novo Nordisk Investigational Site
    Pune, 411011, India
  • Novo Nordisk Investigational Site
    Cheras, 56000, Malaysia
  • Novo Nordisk Investigational Site
    Kota Bharu, Kelantan, 16150, Malaysia
  • Novo Nordisk Investigational Site
    Pulau Pinang, 10990, Malaysia
  • Novo Nordisk Investigational Site
    Kosice, 04190, Slovakia
  • Novo Nordisk Investigational Site
    Lubochna, 03491, Slovakia
  • Novo Nordisk Investigational Site
    Moldava nad Bodvou, 045 01, Slovakia
  • Novo Nordisk Investigational Site
    Zilina, 01001, Slovakia
  • Novo Nordisk Investigational Site
    Zilina, 01207, Slovakia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2007 to primary completion in Feb 2008, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2007
First posted
Aug 30, 2007
StartActual
Aug 30, 2007
Primary completionActual
Feb 28, 2008
CompletionActual
Feb 28, 2008
Results delay requested
Sep 3, 2018
Last update
Sep 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00523042
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 30, 2007
Start date
Aug 30, 2007
Primary completion
Feb 28, 2008
Completion
Feb 28, 2008
Last update
Sep 5, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion